ATE368742T1 - Aminoterminalen verkürzten c-c chemokine und als chemokine antagonist - Google Patents

Aminoterminalen verkürzten c-c chemokine und als chemokine antagonist

Info

Publication number
ATE368742T1
ATE368742T1 AT04007579T AT04007579T ATE368742T1 AT E368742 T1 ATE368742 T1 AT E368742T1 AT 04007579 T AT04007579 T AT 04007579T AT 04007579 T AT04007579 T AT 04007579T AT E368742 T1 ATE368742 T1 AT E368742T1
Authority
AT
Austria
Prior art keywords
aminoterminal
chemokines
shortened
chemokine antagonist
chemokine
Prior art date
Application number
AT04007579T
Other languages
English (en)
Inventor
Paul W Proost
Sofie Struyf
Damme Jo Van
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE368742(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE368742T1 publication Critical patent/ATE368742T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT04007579T 1997-09-29 1998-09-28 Aminoterminalen verkürzten c-c chemokine und als chemokine antagonist ATE368742T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (de) 1997-09-29 1997-09-29 Aminoterminalen verkürzten C-C Chemokine als Chemokine Antagonist
EP97122471A EP0905240A1 (de) 1997-09-29 1997-12-19 Aminoterminalen verkürzten C-C-chemokine and als chemokine Antagonist
EP98104216A EP0905241A1 (de) 1997-09-29 1998-03-10 Aminoterminalen verkürzten C-C Chemokine und als Chemokine Antagonist

Publications (1)

Publication Number Publication Date
ATE368742T1 true ATE368742T1 (de) 2007-08-15

Family

ID=8227408

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04007579T ATE368742T1 (de) 1997-09-29 1998-09-28 Aminoterminalen verkürzten c-c chemokine und als chemokine antagonist
AT98951476T ATE263242T1 (de) 1997-09-29 1998-09-28 Aminoterminal verkürztes rantes als chemokin antagonist
AT98947553T ATE264390T1 (de) 1997-09-29 1998-09-28 Aminoterminal verkürztes mcp-2 als chemokin antagonist

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT98951476T ATE263242T1 (de) 1997-09-29 1998-09-28 Aminoterminal verkürztes rantes als chemokin antagonist
AT98947553T ATE264390T1 (de) 1997-09-29 1998-09-28 Aminoterminal verkürztes mcp-2 als chemokin antagonist

Country Status (28)

Country Link
US (5) US6977071B2 (de)
EP (6) EP0906954A1 (de)
JP (2) JP4233214B2 (de)
KR (2) KR100542934B1 (de)
CN (3) CN1145693C (de)
AR (2) AR013529A1 (de)
AT (3) ATE368742T1 (de)
AU (2) AU750606B2 (de)
BG (2) BG64757B1 (de)
BR (2) BR9812394A (de)
CA (2) CA2305017A1 (de)
CY (1) CY1110927T1 (de)
CZ (2) CZ299478B6 (de)
DE (3) DE69823218T2 (de)
DK (3) DK1439231T3 (de)
EA (2) EA003940B1 (de)
EE (2) EE200000152A (de)
ES (3) ES2215324T3 (de)
HU (2) HU226468B1 (de)
IL (2) IL135351A (de)
NO (2) NO20001584D0 (de)
NZ (3) NZ503234A (de)
PL (2) PL196427B1 (de)
PT (3) PT1019507E (de)
SK (2) SK286495B6 (de)
UA (2) UA73081C2 (de)
WO (2) WO1999016876A1 (de)
ZA (2) ZA988676B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO1999028474A2 (en) * 1997-12-01 1999-06-10 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services Chemokine variants and methods of use
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
ES2272329T3 (es) * 1999-10-25 2007-05-01 Pharis Biotec Gmbh Quimioquinina humana phc-1 procesada.
EP1167527A1 (de) * 2000-06-22 2002-01-02 Euroscreen S.A. Prozessierte Menschliche Chemokine: PHC-1 und PHC-2
WO2001036459A2 (en) * 1999-11-15 2001-05-25 Forssmann Wolf Georg Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
WO2003051921A1 (en) 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Chemokine mutants acting as chemokine antagonists
EP1631680A2 (de) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostika und therapeutika für dipeptidylpeptidase iv (dpp4) assoziierte erkrangkungen
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
CA2695237A1 (en) 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
WO2011097567A1 (en) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity
JP5975886B2 (ja) 2010-03-11 2016-08-23 ヘルス リサーチ インコーポレイテッドＨｅａｌｔｈ Ｒｅｓｅａｒｃｈ， Ｉｎｃ． Ｆｃ融合タンパク質を含む、免疫応答を増強するための方法および組成物
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
CA3101052A1 (en) 2018-05-28 2019-12-05 ORION Biotechnology Switzerland Sarl Methods of inhibiting cerebral inflammation
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
CZ290850B6 (cs) * 1994-12-08 2002-10-16 Glaxo Group Limited Polypeptid, způsob jeho výroby, kódující DNA nebo RNA, vektor a buňka
AU1532697A (en) * 1996-01-12 1997-08-01 Genetics Institute Inc. Beta-chemokine, h1305 (mcp-2)
EP0889961A2 (de) * 1996-03-27 1999-01-13 Icos Corporation Monozyte chemotaktisches protein-5 stoffe und verfahren
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
EE200000152A (et) 2001-02-15
EP1439231A3 (de) 2004-12-22
DE69823218D1 (de) 2004-05-19
CN1145693C (zh) 2004-04-14
UA73080C2 (en) 2005-06-15
US6977071B2 (en) 2005-12-20
CZ299478B6 (cs) 2008-08-06
PT1439231E (pt) 2007-08-20
US20030119148A1 (en) 2003-06-26
HUP0003563A2 (hu) 2001-02-28
HUP0003505A2 (hu) 2001-02-28
NZ516027A (en) 2003-05-30
CN1233415C (zh) 2005-12-28
HK1062637A1 (en) 2004-11-19
EP1021541B1 (de) 2004-04-14
KR20010024213A (ko) 2001-03-26
DK1019507T3 (da) 2004-07-19
NO20001584L (no) 2000-03-27
EP1439231A2 (de) 2004-07-21
ZA988675B (en) 1999-11-24
SK286495B6 (sk) 2008-11-06
ZA988676B (en) 1999-12-03
CN1490049A (zh) 2004-04-21
KR100542934B1 (ko) 2006-01-11
CY1110927T1 (el) 2015-06-10
US7326411B2 (en) 2008-02-05
AU9747498A (en) 1999-04-23
BG64757B1 (bg) 2006-02-28
JP2001518296A (ja) 2001-10-16
US20030124677A1 (en) 2003-07-03
PT1021541E (pt) 2004-07-30
AR013528A1 (es) 2000-12-27
US6905676B2 (en) 2005-06-14
US7338653B2 (en) 2008-03-04
NZ503235A (en) 2002-08-28
PT1019507E (pt) 2004-06-30
CZ299479B6 (cs) 2008-08-06
EA200000378A1 (ru) 2000-10-30
BG64679B1 (bg) 2005-11-30
CZ20001146A3 (cs) 2000-09-13
BR9812394A (pt) 2000-09-12
AU9442098A (en) 1999-04-23
BG104267A (en) 2000-11-30
WO1999016877A1 (en) 1999-04-08
JP2001518297A (ja) 2001-10-16
EP1019507A1 (de) 2000-07-19
ES2287601T3 (es) 2007-12-16
CA2305017A1 (en) 1999-04-08
NO20001584D0 (no) 2000-03-27
ATE263242T1 (de) 2004-04-15
CZ20001147A3 (cs) 2000-09-13
WO1999016876A1 (en) 1999-04-08
UA73081C2 (en) 2005-06-15
EP1439231B1 (de) 2007-08-01
CN1148447C (zh) 2004-05-05
CA2304827A1 (en) 1999-04-08
EP1021541A1 (de) 2000-07-26
DE69823218T2 (de) 2004-08-26
IL135352A (en) 2006-08-20
US20050201977A1 (en) 2005-09-15
EP0905240A1 (de) 1999-03-31
SK286439B6 (sk) 2008-10-07
HK1032426A1 (en) 2001-07-20
EA200000379A1 (ru) 2000-10-30
EA003942B1 (ru) 2003-10-30
US20050220790A1 (en) 2005-10-06
KR100560275B1 (ko) 2006-03-10
PL197569B1 (pl) 2008-04-30
HU226468B1 (en) 2008-12-29
SK4512000A3 (en) 2000-09-12
AR013529A1 (es) 2000-12-27
DE69838188D1 (de) 2007-09-13
HUP0003563A3 (en) 2005-11-28
HU226414B1 (en) 2008-11-28
DE69822856T2 (de) 2004-08-19
DK1439231T3 (da) 2007-11-05
AU750341B2 (en) 2002-07-18
KR20010024214A (ko) 2001-03-26
PL339545A1 (en) 2000-12-18
EP1019507B1 (de) 2004-03-31
JP4230659B2 (ja) 2009-02-25
EA003940B1 (ru) 2003-10-30
US20050164936A1 (en) 2005-07-28
DE69822856D1 (de) 2004-05-06
BR9812565A (pt) 2000-08-01
PL339559A1 (en) 2000-12-18
IL135351A (en) 2006-08-20
PL196427B1 (pl) 2008-01-31
CN1271385A (zh) 2000-10-25
SK4502000A3 (en) 2000-09-12
ES2218860T3 (es) 2004-11-16
ATE264390T1 (de) 2004-04-15
ES2215324T3 (es) 2004-10-01
DK1021541T3 (da) 2004-08-02
HK1032425A1 (en) 2001-07-20
EE200000151A (et) 2001-02-15
NZ503234A (en) 2002-06-28
JP4233214B2 (ja) 2009-03-04
BG104266A (en) 2000-11-30
AU750606B2 (en) 2002-07-25
EP0905241A1 (de) 1999-03-31
NO20001609L (no) 2000-03-28
CN1271386A (zh) 2000-10-25
NO20001609D0 (no) 2000-03-28
EP0906954A1 (de) 1999-04-07
HUP0003505A3 (en) 2005-11-28
DE69838188T2 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
ATE368742T1 (de) Aminoterminalen verkürzten c-c chemokine und als chemokine antagonist
FI973446L (fi) Bentsyylipiperidiinit ja piperatsiinit muskariiniantagonisteina
PT1204663E (pt) Novos compostos espiro com actividade antagonista do neuropeptido y
ID18003A (id) Antagonis muskarinik
FI971685A7 (fi) Takykiniini-antagonisteja
DE69818248D1 (de) Chinolin- und chinazolin-derivate als crf antagonisten
NO980546D0 (no) Farmasöytiske midler
NO20015367L (no) Pegylert interferon alfa-CCR5-antagonistkombinasjons HIV- terapi
ATE232526T1 (de) 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten
NO20001514D0 (no) Vitronectin-reseptor-antagonist
IL145851A0 (en) Osteopontin-derived chemotactic and inhivitory agents and uses therefor
DE69812721D1 (de) Metallocorrinoide als biologisch kompatible pharmakologische mittel
ATE240954T1 (de) Oxazolidinone als 5-ht2a-antagonisten
DE60009931D1 (de) Muscarin-antagonisten
ATE325118T1 (de) Piperazinoderivate als neurokinin-antagonisten
DE69732715D1 (de) Tachykinin antagoniste
NO20015068L (no) Nye 8A- og 9A-15-ringlaktamer
ATE227582T1 (de) Chemokin rezeptor antagonist und cyclosporin in kombinationstherapie
EP1229795A4 (de) Menschliches chemokine beta-13
NO20015966D0 (no) Tricykliske analgetika
DK0964867T3 (da) Tachykininantagonister
IL135352A0 (en) Truncated mcp-2 as chemokine antagonist
DE59710062D1 (de) Büro- und arbeitsmöbel
SE9904414D0 (sv) Pharmaceutical composition and use
EE00101U1 (et) Püstkiik

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1439231

Country of ref document: EP

EEFA Change of the company name